MAM
ADPT icon

Meeder Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Meeder Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,632
Closed -$43K – 595
2022
Q4 		$43K Buy
5,632
+4,523
+408% +$35.2K ﹤0.01% 537
2022
Q3 		$8K Buy
1,109
+522
+89% +$4.92K ﹤0.01% 1386
2022
Q2 		$5K Buy
587
+293
+100% +$2.58K ﹤0.01% 1623
2022
Q1 		$4K Buy
+294
New +$4.62K ﹤0.01% 1836
2021
Q4 		– Sell
-33
Closed -$1K – 1112
2021
Q3 		$1K Sell
33
-7
-18% -$253 ﹤0.01% 2269
2021
Q2 		$2K Hold
40
– – ﹤0.01% 2176
2021
Q1 		$2K Hold
40
– – ﹤0.01% 2047
2020
Q4 		$2K Hold
40
– – ﹤0.01% 1440
2020
Q3 		$2K Sell
40
-8
-17% -$336 ﹤0.01% 1792
2020
Q2 		$2K Sell
48
-18
-27% -$656 ﹤0.01% 1736
2020
Q1 		$2K Buy
66
+60
+1,000% +$1.67K ﹤0.01% 2050
2019
Q4 		$0 Buy
+6
New +$172 ﹤0.01% 2221

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Meeder Asset Management's ADPT Position: Q1 2023 in Review

Meeder Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 5,632 shares — an estimated $43K sold.

Meeder Asset Management first reported a position in ADPT in Q4 2019 and held it in 12 quarters. The position peaked at $43K in Q4 2022. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

  • Meeder Asset Management reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Meeder Asset Management sold 5,632 Adaptive Biotechnologies shares in Q1 2023, an estimated $43K.
  • Meeder Asset Management first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 12 quarters.
  • Meeder Asset Management's Adaptive Biotechnologies position peaked at $43K in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Meeder Asset Management's 13F filing for Q1 2023, filed 15 May 2023.